[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352419-105":59,"doc-detail-352419-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","evaluating-deconvolution-methods-using-real-bulk-rna-expression-data-for-robust-prognostic-insights-across-cancer-types","Evaluating deconvolution methods using real bulk RNA-expression data for robust prognostic insights across cancer types","","Deconvolution of bulk RNA-expression data can reveal cancer cellular complexity, but pseudobulk benchmarks may fail when absolute cell proportions are unknown in real-world samples. This study introduces a real-data benchmarking framework using 18 bulk RNA-expression cohorts (5,891 samples) across nine cancer types to test five deconvolution methods via differentially proportioned and prognosis-related cell types. Across three benchmark scenarios, ReCIDE and BayesPrism show robust performance, and pan-cancer analysis identifies mCAF and a classical monocytes+mCAF indicator as prognostic markers validated in GEO cohorts.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluating-deconvolution-methods-using-real-bulk-rna-expression-data-for-robust-prognostic-insights-across-cancer-types/352419/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluating-deconvolution-methods-using-real-bulk-rna-expression-data-for-robust-prognostic-insights-across-cancer-types/352419.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"为什么传统的伪批量（pseudobulk）基准可能不可靠？","Question",{"text":113,"@type":114},"真实批量样本中绝对细胞比例通常未知，而伪批量基准可能无法反映这一现实条件，导致方法表现与临床可用性不一致。","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"研究如何在真实数据中评估去卷积方法？",{"text":118,"@type":114},"作者使用18个真实批量RNA表达队列、共5,891个样本，跨九种癌症类型，基于差异比例（DP）与与预后相关（PR）的细胞类型设置三个基准场景来评估五种去卷积方法。",{"name":120,"@type":111,"acceptedAnswer":121},"哪些去卷积方法在基准中表现最稳健？",{"text":122,"@type":114},"在一致性与可重复性相关的三个创新基准场景中，ReCIDE与BayesPrism被发现是两种表现更稳健的去卷积方法。",{"name":124,"@type":111,"acceptedAnswer":125},"研究发现了哪些与预后相关的细胞标志物？",{"text":126,"@type":114},"跨癌种分析中，矩阵相关肿瘤成纤维细胞（mCAF）被识别为预后标志物；进一步组合“经典单核细胞+ mCAF”的细胞比例在多个TCGA队列中显著，并在独立的GEO队列中得到验证。","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},352419,1790144945,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Li etal. Genome Biology (2026) 27:38 Genome Biology  \n[https://doi.org/10.1186/s13059-026-03942-1](https://doi.org/10.1186/s13059-026-03942-1)  \nRESEARCH Open Access  \nEvaluating deconvolution methods using real bulk RNA-expression data for robust prognostic insights across cancer types  \nMinghan Li1†, Yuqing Su1†, Yizhou Tang1, Yuehfan Lee1 and Weidong Tian1,2,3*  \n\n| †Minghan Li andYuqing Su contributed equally to this work. |\n| --- |\n| *Correspondence: [weidong.tian@fudan.edu.cn](weidong.tian@fudan.edu.cn) |\n\n1 State Key Laboratory of Genetic Engineering, Department of Computational Biology, School of Life Sciences, Fudan University, Shanghai, China  \n2 Children’s Hospital of Fudan University, Shanghai, China  \n3 Children’s Hospital of Shandong University, Jinan, China  \nAbstract  \nBackground: Deconvolution of bulk RNA-expression data unlocks the cellular complexity of cancer, yet traditional pseudobulk benchmarks may not always be reliable in real-world settings where absolute cell proportions are unknown.  \nResults: Here, we introduce a novel real-data framework, leveraging 18 real bulk RNAexpression cohorts (5,891 samples) across nine cancer types to evaluate five deconvolution methods based on differentially proportioned (DP) and prognosis-related (PR) cell types. Across three innovative benchmark scenarios—consistency with scRNAseq, reproducibility across cohorts, and reproducibility of prognostic relevance—ReCIDE and BayesPrism stand out as two robust deconvolution methods. Application of a pan-cancer analysis based on the deconvolution of TCGA cohorts identifies matrix cancer-associated fibroblasts (mCAF) as a prognostic marker with consistent effects across multiple cancers. Building on this finding, we find a prognostic indicator combining classical monocytes and mCAF cell proportions to be significant in five TCGA cohorts, which we further validate in five independent GEO cohorts.  \nConclusions: This study broadens deconvolution benchmarking, offering actionable tools for precision oncology and guiding method selection for translational research.  \nIntroduction  \nThe cellular heterogeneity of cancer critically impacts patient outcomes and treatment strategies, yet unraveling this complexity in clinical samples remains a difficult task [1–4]. Single-cell RNA sequencing (scRNA-seq) has begun to pierce this veil, revealing gene expression at unprecedent resolution [5–7], but its cost restricts large-scale studies linking cell types to patient prognosis [8]. Conversly, bulk RNA-seq and microarray data from repositories like TCGA and GEO [9–12], rich with clinical information, offera scalable alternative. Deconvolution methods bridge these domains, estimating cell type proportions from bulk data using scRNA-seq references to probe disease associations [13, 14].  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/licenses/by/4.0/](creativecommons.org/licenses/by/4.0/.)[.](creativecommons.org/licenses/by/4.0/.)  \nLi etal. Genome Biology (2026) 27:38 Page 2 of 23  \nYet, a notable challenge persists. Despite advances in methods like CIBERSORT [15], DWLS [16], MuSiC [17], Bisque [18], BayesPrism [19], and our r","cbCaiax4Y0kok3ZO","https://ap.wps.com/l/cbCaiax4Y0kok3ZO","pdf",6800122,23,"English","# Abstract\n## Results\n### Benchmark design\n# Introduction\n# Results\n## Benchmark design\n# Conclusions","[{\"question\":\"为什么传统的伪批量（pseudobulk）基准可能不可靠？\",\"answer\":\"真实批量样本中绝对细胞比例通常未知，而伪批量基准可能无法反映这一现实条件，导致方法表现与临床可用性不一致。\"},{\"question\":\"研究如何在真实数据中评估去卷积方法？\",\"answer\":\"作者使用18个真实批量RNA表达队列、共5,891个样本，跨九种癌症类型，基于差异比例（DP）与与预后相关（PR）的细胞类型设置三个基准场景来评估五种去卷积方法。\"},{\"question\":\"哪些去卷积方法在基准中表现最稳健？\",\"answer\":\"在一致性与可重复性相关的三个创新基准场景中，ReCIDE与BayesPrism被发现是两种表现更稳健的去卷积方法。\"},{\"question\":\"研究发现了哪些与预后相关的细胞标志物？\",\"answer\":\"跨癌种分析中，矩阵相关肿瘤成纤维细胞（mCAF）被识别为预后标志物；进一步组合“经典单核细胞+ mCAF”的细胞比例在多个TCGA队列中显著，并在独立的GEO队列中得到验证。\"}]","Evaluating deconvolution methods using real bulk RNA-expression data for robust prognostic insights across cancer types | PDF",1790099449,58,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57f1cd6f31bfc9fbc3e1249ec76f5781.webp",983,1305,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9384f2a16d68027784d81be79ab9a275.webp",982,1304,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed2cf145e2ddac41c8950d173cb82a0a.webp",981,1303,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63c00613681ebd9e99db9857fc50fab6.webp",980,1301]